Decipher Labs Ltd (DECIPHER) — shareholding pattern, promoter holding, financials and share price
About Decipher Labs Ltd (DECIPHER)
Decipher Labs Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as DECIPHER and on the BSE under scrip code 524752. Its ISIN is INE643N01012.
Incorporated in 1986, Decipher Labs Ltd deals in pharma and consultancy business. [1]
Decipher Labs Ltd., formerly known as Combat Drugs Ltd, is a diversified public company engaged in manufacturing and marketing pharmaceuticals and providing IT solutions.
The company has expanded its operations with the acquisition of Decipher Software Solutions LLC in the USA, indicating a strategic focus on IT solutions.
Listed peers in Pharmaceuticals: Colinz Laboratories Ltd, Vivanza Biosciences Ltd, Ganga Pharmaceuticals Ltd, Brawn Biotech Ltd, Fabino Enterprises Ltd, Shyama Computronics and Services Ltd.
Valuation & Returns
10 Jul 2026At ₹6.06 a share on 10 Jul 2026, Decipher Labs Ltd (DECIPHER) was valued at a price-to-book of 0.27x on a book value of ₹22.63 per share as of Mar 2025. Solomo computes return on equity of -18.86% and return on capital employed of -15.93% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- Industry P/E
- 36.41x
- P/B
- 0.27x
- EPS (TTM)
- ₹-4.27
- Book value / share
- ₹22.63
- ROE
- -18.86%
- ROCE
- -15.93%
- ROA
- -16.73%
- Debt / equity
- 0.01x
- Dividend yield
- 0%
- EBITDA margin
- -22.65%
- 52-week range
- ₹5 – ₹11.95
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Decipher Labs Ltd (DECIPHER) reported revenue of ₹14.05 crore, net profit of ₹-3.08 crore and earnings per share of ₹-3.05. That compares with revenue of ₹22.61 crore and net profit of ₹-5.08 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹3.6 crore and net profit ₹-0.36 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 65.32 | 45.57 | 35.88 | 22.61 | 14.05 |
| Net profit (₹ cr) | 11.38 | -2.68 | -1.68 | -5.08 | -3.08 |
| EPS (₹) | 11.27 | -2.65 | -1.66 | -5.03 | -3.05 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 16.08% | -9.73% | -4.78% | -36.98% |
| Profit growth | - | - | - | -202.38% |
| Stock price CAGR | 7% | -29% | -27% | -44% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 16.43% of Decipher Labs Ltd (DECIPHER) (unchanged from the previous quarter), foreign institutional investors (FII) hold 0%. Market capitalisation was ₹6 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2004.
Largest disclosed public shareholders in Jun 2026: SESHU SRINIVAS AKULA 3.8%, HUF 2.32%, SUSHANT MOHAN LAL 2.14%, SURIADOSS ELUMALAI 1.42%, SHRI KRISHNA MAHESHWARI(HUF) 1.37%, CYRIL SEBASTIAN 1.2%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 16.43% | - | 0% | - | 83.57% |
| Mar 2026 | 16.43% | - | 0% | - | 83.57% |
| Dec 2025 | 16.43% | - | - | 0% | 83.57% |
| Sep 2025 | 16.43% | - | - | 0% | 83.57% |
| Jun 2025 | 16.43% | - | - | 0% | 83.57% |
| Mar 2025 | 16.43% | - | - | 0% | 83.57% |
| Dec 2024 | 16.43% | - | - | 0% | 83.57% |
| Sep 2024 | 16.43% | - | - | 0% | 83.57% |